Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
LIVE INFECTIOUS BURSAL DISEASE (IBD) VIRUS STRAIN, WINTERFIELD 2512, G-61
Ceva Santé Animale
QI01AD09
LIVE INFECTIOUS BURSAL DISEASE (IBD) VIRUS STRAIN, WINTERFIELD 2512, G-61
min. 2.0
Lyophilisate for suspension
POM
Fowl - Chicken
Avian infectious bursal disease virus vaccine (Gumboro disease)
Immunological - Live Vaccine
Authorised
2012-12-14
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Cevac IBD 2512 L lyophilisate for oral suspension for chickens 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One dose contains: ACTIVE SUBSTANCE: Live avian infectious bursal disease (IBD) virus, strain Winterfield 2512, G-61 2.0 log 10 to 3.2 log 10 EID 50 */dose * EID 50 – embryo infectious dose 50% EXCIPIENTS: For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Lyophilisate for oral suspension. Blue freeze-dried powder. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Chickens (broilers) 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the active immunization of broiler chickens from 10 days of age with maternally-derived antibodies against avian infectious bursal disease (IBD, Gumboro disease), to reduce mortality, clinical symptoms, weight loss and acute lesions in bursa of Fabricius, caused by very virulent infectious bursal disease virus. Onset of immunity: 14 days post-vaccination. Duration of immunity: 27 days post-vaccination. 4.3 CONTRAINDICATIONS Do not use in infected flocks with clinical symptoms. Do not use for immunisation of flocks without maternally derived antibodies (MDA). (See section 4.5.). 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES The vaccine contains an “intermediate-plus” virus strain that is known to cause immunosuppression and bursal damage when inoculated into birds without MDA (see sections 4.5, 4.6 and 5.). Consequently, the vaccine is only indicated for immunisation of chicken having maternal antibodies and exposed to very virulent IBD virus strains. H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ _ Read the complete document